

Current Status of Biosimilar Regulations in the MENA Region

Ammar Almaaytah^{1,2}, Hadeia Mashaqbeh^{2§}, Razan Haddad^{2§}

1 Department of Pharmacy, Faculty of Pharmacy, Middle East University, Amman, Jordan

2 Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan

§ Both authors contributed equally to this work.

Corresponding Author: Ammar Almaaytah, Email: aalmaaytah@meu.edu.jo,
Phone: +962777658820

Abstract:

This review article explores the regulatory situation of biosimilar registration pathways in the Middle East and North Africa (MENA). With most countries in the world have either adopted official regulatory guidelines for biosimilar approval or are in the process of developing such guidelines, countries in the MENA region are advised to accelerate the process of the adopting official pathways for biosimilar approval primarily for preventing the entry of intended copies into such markets and risking patients' safety in addition to jeopardizing clinical outcomes of the different disease modalities that are treated by biologics. Additionally, biosimilars are playing a major role in reducing the significant public expenditure on biological therapy and thus increasing the accessibility of these medications to a larger population of patients. The article details the countries in the MENA region that have adopted official and scientific guidelines for biosimilar approval pathways. The article also draws a comparison between different countries on issues such as comparability studies, extrapolation of indications, interchangeability and non-clinical quality requirements. In conclusion, only four countries out of the 15 countries the comprise the MENA region have adopted clear regulatory pathways for biosimilar registration and approval.

This situation should be of urgent importance to policy makers responsible for public health bodies in countries that lack such guidelines due to the negative consequences that could result due to the absence clear biosimilar regulations.

Keywords: Biosimilars; Biologics; MENA; EMA; Regulatory.

Introduction

The introduction of biological medicinal products in the early 80's has revolutionized the treatment of several disease modalities including cancer, autoimmune diseases and hormonal deficiencies [1, 2, 3]. Unlike their chemical medicinal counterparts, biological products are synthesized based on a recombinant DNA technology and in living organisms such as bacteria, yeast and mammalian cells [4]. The resultant protein products are of high structural complexity when compared with their classical chemical counterparts due to the three dimensional topology of proteins when synthesized within biological systems and the several variables influencing the manufacturing process of each biological entity [4]. This complexity in structure has resulted in the difficulty of establishing a fast track generic industry for these molecules by the pharmaceutical industry as there were no technical and regulatory pathways to create such generic products and introduce them into markets [5]. However, and due to the huge profitability of biological molecules and the fact that several of them lost their patent exclusivity, several pharmaceutical companies embarked on developing generic products of biologics in order to compete with their originator counterparts and to seize the huge economic opportunity

in pursuit of gaining marketing authorization to introduce these generic bioreplicas into the market [6]. The term biosimilar was introduced to describe any copy of the originator branded biological molecule which could demonstrate a high comparability to the originator in a highly rigorous clinical and non-clinical comparability exercise [7]. Additionally, the high cost of originator biologics and the entry of several agents of these into the clinic created a huge financial pressure on the public health sector of several countries that offer full coverage public health insurance for their citizens [8]. This in turn incited several regulatory bodies within different countries to develop guidelines for biosimilar approval and registration with the aim of reducing public expenditure and expanding the therapeutic options available to the public [9]. The first regulatory entities that were eager to adopt and accelerate the development of such guidelines were members of the European union as all these countries adopt a full health insurance coverage to their citizens and the establishment of a biosimilar registration pathway would ensure cutting public expenditure while conserving the quality and safety of health outcomes that are related to originator biologics [10]. Accordingly, the first guidelines for the registration pathway of biosimilar drugs was developed by the European Medicines Agency [EMA] in 2005 which was followed in 2006 by the regulatory approval of the first biosimilar in Europe Omnitrope® [A biosimilar recombinant growth hormone] by Sandoz Pharmaceuticals in Austria [11]. Since then, more than 20 biosimilars have been approved and over 11

applications are being reviewed by the agency [12]. The development of a regulatory pathway for biosimilar approval in the European Union has also been followed by the development and creation of regulatory pathways for biosimilar approval in most developed regions including North America, Latin America and Asia [13, 14, 15]. In the Middle East and North Africa, the regulatory pathways for regulatory approval are still variable between different countries with some having no regulatory pathway at all for biosimilar drugs and other with no specific guidelines and thus allowing the approval and registration of intended copies or biomimetics as generic medications and thus compromising the quality of these medications and exposing the patients to significant safety issues. Most of the countries that have standardized regulatory pathways for biosimilar approval such as Jordan, Saudi Arabia, Lebanon and Egypt have adopted international standards for the comparability exercise of a biosimilar versus its originator biological such as the EMA, FDA and WHO guidelines [16, 17]. However, there still remain several countries with no standardized guidelines whatsoever such as Libya, Morocco, Tunisia, Algeria, Yemen, Syria, Iraq and the Gulf countries. The aim of the review is to focus on two major issues regarding the regulatory situation in the MENA region, the first is to differentiate between countries that have scientific and rigorous guidelines for biosimilar approval from those who do not and the second is to highlight and draw a comparison between the standardized pathways which have adopted these guidelines in four main issues and these

include: comparability studies, extrapolation of indication, interchangeability and Non-clinical quality attributes of biosimilars.

Comparability Studies

According to the EMA guidelines and for regulatory approval, comparing a biosimilar with a publically available standard such as a pharmacopeial monograph is not sufficient for the demonstration of comparability with the reference product. [18]. A biosimilar has to prove a high level of similarity with the reference product in an extensive comparability exercise with regards to quality, safety and efficacy. This requires biosimilar manufacturers to produce preclinical, clinical and immunogenicity studies to confirm sufficient similarity with the originator biologic. Un-abiding to these guidelines or not setting any guidelines such as the ones adopted by the EMA will risk the possibility of having a “biomimic” or an intended copy to obtain registration pathway for a molecule that is treated from a regulatory point of view as a generic and consequently exposing the patients to either an inferior molecule or a molecule with serious safety risks [19]. In the MENA region only four countries have clear guidelines for manufacturers to produce comparability studies when submitting their registration dossier. These countries include Jordan, Saudi Arabia, Egypt and Lebanon. The most stringent and detailed guidelines in terms of the comparability exercise are the Jordanian and Egyptian guidelines which clearly state that both clinical and non-clinical studies between the

originator and the biosimilar must be included in the registration dossier. The Saudi and Lebanese guidelines state that a head to head comparability exercise must be included in the regulatory dossier of the biosimilar but lack details of the clinical requirements of the biosimilar. Figure 1 represents a map detailing the regulatory status of biosimilars in the MENA region. As most of the MENA countries still lack regulatory pathways for the identification of a biosimilar drug and either adopt standard generic pathways for marketing authorization for biosimilars or lack none. This situation creates a significant health issue for the population of these countries as several “intended copies” could be used for the treatment of serious diseases and consequently jeopardizing the health and safety of the patients. Local health authorities in these countries should fast forward the process of introducing proper legislation to create legal pathways for biosimilar registration in order to protect patients and achieve maximal health benefit outcomes.




Figure 1: Regulatory situation of Biosimilars in the MENA region

Extrapolation of Indications

The extrapolation of indications for biosimilars remains somehow controversial among regulatory authorities. Extrapolation of indications for a follow-up biosimilar from one indication to all indications of the reference biological product is possible as long as the biosimilar meets certain safety and efficacy criteria provided in the tested indication [20]. The EMA guidelines set specific criteria for indication extrapolation and these include: (1) a sensitive clinical model to predict the potential differences between the biosimilar and its

reference product; (2) The mechanism of action regarding the target receptor should be identical; (3) Safety and immunogenicity data of the biosimilar have been extensively characterized [21]. In the MENA region, The Egyptian and Lebanese guidelines provide a clear set of criteria for biosimilar extrapolation of indications which is mainly based on the EMA guidelines. The Jordanian guidelines allow for extrapolation and mention that receptor identity is crucial for the extrapolation exercise but do not target the clinical sensitivity models outlined in the EMA and WHO guidelines. The Saudi biosimilar guidelines allow extrapolation but do not set detailed criteria for the manufacturers regarding the criteria and scientific requirements to allow biosimilar extrapolation and leave the issue for a case by case regulatory decision.

Table 1 includes a comparative summary of all regulatory aspects of biosimilar approval according to EMA, WHO and the MENA countries.

Interchangeability and Automatic Substitution

The subject of biosimilar interchangeability and automatic substitution is vaguely addressed by international regulatory authorities and this has serious consequences specifically in countries where medications are supplied by the government on a tender based national procurement process. The EMA has no guidelines on interchangeability and leaves the decision and advice to the drug regulatory authorities within the European Union. The WHO guidelines are similar to that of EMA's as the decision is left to be regulated by national

authorities. In the MENA region, Both Jordanian and Egyptian guidelines clearly state the automatic substitution at the Pharmacy level is not allowed and switching is the sole responsibility of the treating health professional. The Saudi and Lebanese guidelines do not mention any guidelines whatsoever regarding interchangeability or automatic substitution. This situation is more complicated by the fact that interchangeability is being performed on a national level in most MENA countries within the Public health sector as drug procurement is tender based and depends on the generic name of the molecule which leads to the introduction of the biosimilar automatically and leaves no alternatives to health professionals for any clinical decisions regarding biosimilar substitution or interchangeability. This situation requires international and national health authorities to clarify the concept the governmental bodies responsible for biological drugs procurement.

Non-Clinical Requirements

The most detailed regulatory guidelines regarding biosimilar registration concern the non-clinical quality part of the registration dossier. According to EMA guidelines, any biosimilar must perform full and complete comparative *in vitro* studies that include: (1) Pharmacology; (2) Pharmacodynamics; (3) Pharmacokinetic; (4) Toxicology; and Immunogenic studies. All MENA countries specify the need for all studies mentioned above. Additionally, EMA regulations state that *in vivo* studies are not considered necessary but the

Jordanian and the Egyptian guidelines require the performance animal *in vivo* studies to confirm the pharmacological, toxicological and immunogenic data regarding the quality of the biosimilar.

Conclusion

The governmental regulations of biosimilar marketing authorization based on scientific and clinically rigorous data is needed to ensure patient safety and drug efficacy. The lack of such regulations or the absence of rigorous regulatory pathways for biosimilar assessment and evaluation allows the entry of intended copies of the originator biological molecules and consequently threatening the patients' safety and optimal health treatment outcomes. Additionally, the complete absence of biosimilar guidelines or marketing authorization pathways of biosimilars will reduce patients' accessibility to biological therapy as these medications are significantly costly and represent a financial burden to public health authorities. As biosimilars are of reduced cost of an average of 30% when compared to originator biologicals. This article reviews the countries that have adopted such regulations in the MENA region and benchmarks these regulations against EMA guidelines. Only four countries out of the 15 countries the comprise the MENA region have adopted clear regulatory pathways for biosimilar registration and approval. This constitutes a serious issue as most countries worldwide have either adopted such guidelines or are in the process of regulating biosimilars. In order to ensure patient safety and treatment

efficacy, regulatory bodies in the MENA region should develop these guidelines either with the cooperation of international health authorities such as the WHO or other special expert committees from neighboring countries.

Funding:

The authors declare no funding was received for the completion of this review.

Acknowledgment:

The authors are grateful to the Middle East University, Amman, Jordan for the financial support granted to cover the publication fee of this research article.

References:

1. Moroder, Luis, and Hans-Jürgen Musiol. "Insulin—from its discovery to the industrial synthesis of modern insulin analogues." *Angewandte Chemie International Edition* 56, no. 36 (2017): 10656-10669.
2. Balagué, Cristina, Steven L. Kunkel, and Núria Godessart. "Understanding autoimmune disease: new targets for drug discovery." *Drug discovery today* 14, no. 19-20 (2009): 926-934.
3. Oldham, Robert K. "Biologicals and biological response modifiers: fourth modality of cancer treatment." *Cancer treatment reports* 68, no. 1 (1984): 221-232.
4. Reichert, Janice M., and Cherie Paquette. "Clinical development of therapeutic recombinant proteins." *BioTechniques* 35, no. 1 (2003): 176-185.
5. Sekhon, Bhupinder Singh, and Vikrant Saluja. "Biosimilars: an overview." *Biosimilars* 1, no. 1 (2011): 1-11.

6. Blackstone, Erwin A., and P. Fuhr Joseph. "The economics of biosimilars." *American health & drug benefits* 6, no. 8 (2013): 469.
7. Kuhlmann, Martin, and Adrian Covic. "The protein science of biosimilars." *Nephrology Dialysis Transplantation* 21, no. suppl_5 (2006): v4-v8.
8. Blackstone, Erwin A., and Joseph P. Fuhr Jr. "Biopharmaceuticals: the economic equation." *Biotechnology healthcare* 4, no. 6 (2007): 41.
9. Gottlieb, Scott. "Biosimilars: policy, clinical, and regulatory considerations." *American Journal of Health-System Pharmacy* 65, no. 14_Supplement_6 (2008): S2-S8.
10. Haustein, Robert, Christoph de Millas, Ariane Höer, and Bertram Häussler. "Saving money in the European healthcare systems with biosimilars." *GaBI J* 1, no. 3-4 (2012): 120-6.
11. Schiestl, Martin, Markus Zabransky, and Fritz Sörgel. "Ten years of biosimilars in Europe: development and evolution of the regulatory pathways." *Drug design, development and therapy* 11 (2017): 1509.
12. GaBI. EMA approval for adalimumab biosimilars Idacio and Kromea [Online]. Available: <http://www.gabionline.net/Biosimilars/News/EMA-approval-for-adalimumab-biosimilars-Idacio-and-Kromea> [Accessed: 3 Mar 2020].
13. Tsai, Wen-Chan. "Update on biosimilars in Asia." *Current rheumatology reports* 19, no. 8 (2017): 47.
14. Garcia, Ricardo, and Denizar Vianna Araujo. "The regulation of biosimilars in Latin America." *Current rheumatology reports* 18, no. 3 (2016): 16.

15. Dougherty, Michele K., Issam Zineh, and Leah Christl. "Perspectives on the current state of the biosimilar regulatory pathway in the United States." *Clinical Pharmacology & Therapeutics* 103, no. 1 (2018): 36-38.
16. Ali, Rana Musa, Wesal Salem Al Haqaish, and Hayel Obeidat. "Biosimilar regulation and approval in Jordan." *Generics and Biosimilars Initiative Journal* 7, no. 2 (2018): 77-80.
17. GaBI. Egypt issues draft guidelines for biosimilars [Online]. Available: <http://www.gabionline.net/Guidelines/Egypt-issues-draft-guidelines-for-biosimilars> [Accessed: 3 Mar 2020].
18. Lee, Jaymi F., Jason B. Litten, and Gustavo Grampp. "Comparability and biosimilarity: considerations for the healthcare provider." *Current medical research and opinion* 28, no. 6 (2012): 1053-1058.
19. Ghia, Canna, Disheet Shah, Gautam Rambhad, Asia Mubashir, and Sundeep Upadhyaya. "Biologics, biosimilars, intended copies and the era of competitive medicine." *Apollo Medicine* 12, no. 2 (2015): 103-111.
20. Weise, Martina, Pekka Kurki, Elena Wolff-Holz, Marie-Christine Bielsky, and Christian K. Schneider. "Biosimilars: the science of extrapolation." *Blood, The Journal of the American Society of Hematology* 124, no. 22 (2014): 3191-3196.
21. Reinisch, Walter, Edouard Louis, and Silvio Danese. "The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13." *Expert review of gastroenterology & hepatology* 9, no. sup1 (2015): 17-26.

Table 1: Comparative summary between biosimilar regulatory pathways worldwide and the MENA region.

	EMA	Jordan	Saudi Arabia	Egypt	Lebanon
Comparability Studies	Comprehensive head-to-head comparison of the biosimilar with the reference medicine to show high similarity in chemical structure, biological function, efficacy, safety and immunogenicity.	Comparative quality, non-clinical and clinical studies are needed to substantiate the similarity of structure/composition, quality, efficacy and safety, immunogenicity.	Side-by-side comparative studies unless otherwise justified	Head-to-head comparison to establish similarity in quality, safety, and efficacy. complete comparability quality exercise	Head-to-head comparison of a bio-therapeutic product with a licensed originator product with the goal to establish similarity in quality, safety, and efficacy.
Extrapolation of Indications	Allows extrapolation of therapeutic indication, safety and efficacy data (fewer clinical trials or no trials at all need). supported by scientific evidence generated in robust comparability studies (quality, non-clinical and clinical).	Extrapolation from one therapeutic indication to another is appropriate where: the mechanism of action and the receptor are known to be the same as the condition(s) for which similarity in efficacy has been established	No clear guidelines regarding extrapolation of indications is mentioned.	Extrapolation of indication could be possible if all the following conditions are met: A sensitive population criterion that is able to detect potential differences between the biosimilar and reference product is used. The clinically relevant mechanism of action.	If similar efficacy and safety of have been demonstrated for a particular clinical indication, extrapolation of these data to other indications of the reference may be possible if all of the following conditions are fulfilled: A sensitive clinical test model has been used, The clinically relevant mechanism of action. Safety and immunogenicity have been sufficiently characterized. if the efficacy trial used a non-inferiority study.
Interchangeability & Automatic Substitution	EMA guidelines state the decision is taken at the national level.	The decision of interchangeability should be taken following the opinion of a qualified health professional.	No Guidelines available	No Guidelines available	Automatic substitution at Pharmacy level is not allowed and interchangeability should be the decision of the Healthcare Professionals only.

Non-Clinical Requirements	Comparative <i>in vitro</i> studies: (Binding to target(s)) should be included. <i>in vivo</i> animal study is usually <u>not</u> considered necessary.	Comparative <i>in vitro</i> and <i>in vivo</i> (animal) studies should be designed. - At least one repeat-dose toxicity study, including toxicokinetic measurements, should be conducted in relevant species.	The regulatory details regarding non-clinical requirements are not explained in detail.	Comparative <i>in vitro</i> and <i>in vivo</i> (animal) studies should be designed.	The regulatory details regarding non-clinical requirements are not explained in detail. Manufacturer should provide data regarding the Pharmacology, pharmacodynamics and Toxicology
----------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

